Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
Figure 4
AML MNC ± drug treatment. Percentages survival (relative to number of cells plated) calculated from hemocytometer counts using trypan blue for (a) AML PB MNCs and (b) AML BM MNCs (n = 5 patients) treated with ara-C, CNDAC or mitoxantrone are shown. PB MNCs were drug-treated in suspension, while BM MNCs were treated in the presence of M2-10B4 stromal layers for 4 days (Day 4). Cells were then washed and replated on M2-10B4 stromal layers for post-drug wash-out analysis on days 7, 14, and 35. *denotes P ≤ 0.05 for particular drug concentrations compared with untreated, and †denotes P ≤ 0.05 for 1 μM CNDAC or 0.005 μM mitoxantrone compared to 1 μM ara-C.
